Orion Portfolio Solutions LLC Sells 40,829 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Orion Portfolio Solutions LLC decreased its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 50.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 40,621 shares of the medical device company's stock after selling 40,829 shares during the quarter. Orion Portfolio Solutions LLC owned about 0.08% of AtriCure worth $1,139,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Champlain Investment Partners LLC increased its position in shares of AtriCure by 4.3% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company's stock valued at $78,253,000 after purchasing an additional 115,813 shares during the period. First Light Asset Management LLC boosted its position in shares of AtriCure by 42.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,964,703 shares of the medical device company's stock valued at $44,736,000 after purchasing an additional 581,843 shares in the last quarter. Hood River Capital Management LLC acquired a new position in shares of AtriCure in the 2nd quarter worth approximately $40,422,000. Wellington Management Group LLP raised its holdings in shares of AtriCure by 0.4% in the 3rd quarter. Wellington Management Group LLP now owns 1,543,896 shares of the medical device company's stock worth $43,291,000 after purchasing an additional 6,045 shares in the last quarter. Finally, State Street Corp boosted its holdings in AtriCure by 4.9% during the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock worth $37,710,000 after buying an additional 63,002 shares in the last quarter. Institutional investors own 99.11% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ATRC. Canaccord Genuity Group raised their price objective on AtriCure from $53.00 to $61.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. StockNews.com upgraded AtriCure from a "sell" rating to a "hold" rating in a report on Saturday, September 14th. Needham & Company LLC upped their price objective on shares of AtriCure from $34.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Oppenheimer lifted their target price on shares of AtriCure from $32.00 to $36.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Finally, UBS Group raised their price objective on shares of AtriCure from $35.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.00.

AtriCure Stock Down 3.4 %

NASDAQ:ATRC traded down $1.12 during mid-day trading on Friday, reaching $31.67. The stock had a trading volume of 494,255 shares, compared to its average volume of 699,184. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.59. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $39.04. The business's 50 day moving average is $32.93 and its 200 day moving average is $27.25. The stock has a market cap of $1.54 billion, a P/E ratio of -38.16 and a beta of 1.40.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The business had revenue of $115.91 million during the quarter, compared to analysts' expectations of $112.23 million. During the same period in the previous year, the company earned ($0.20) earnings per share. AtriCure's revenue for the quarter was up 17.9% on a year-over-year basis. As a group, sell-side analysts predict that AtriCure, Inc. will post -0.72 earnings per share for the current year.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.